Primary Epithelial Neuroendocrine Tumors of the Retroperitoneum

Dehal, Ahmed; Kim, Sean; Ali, Aamna; Walbolt, Thomas

doi:10.7812/tpp/15-058

Cited by 12 publications

(12 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Retroperitoneal NETs were first described by Morgagni in 1761. They are rare tumors which are either primary, mainly originating from the gastrointestinal tract and pancreas, or metastatic, which are far more common than the primary tumor [1] .…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Primary retroperitoneal neuroendocrine tumor with nonspecific presentation: A case report

Taei

Mail

Thinayyan

2020

Radiology Case Reports

View full text Add to dashboard Cite

Primary retroperitoneal tumors are a rare entity of human neoplasms, with primary retroperitoneal neuroendocrine tumors being even more rare. They are usually metastatic and rarely seen as a primary tumor. We report a case of primary retroperitoneal neuroendocrine tumor in a 55-year-old lady, who presented with chronic abdominal pain. Computed tomography showed a retroperitoneal mass and biopsy confirmed the diagnosis of primary retroperitoneal neuroendocrine tumor. Primary retroperitoneal neuroendocrine tumors are rare tumors. Radiology plays a crucial part in the diagnosis of such tumors with the CT scan considers the best imaging modality for diagnosis. Surgical resection remains the definite treatment of retroperitoneal neuroendocrine tumors. Chemotherapy is used for unresectable differentiated tumors.

show abstract

Section: Discussionmentioning

confidence: 99%

“…Primary retroperitoneal neuroendocrine tumors (NETs) account for only 0.16% to 0.20% of all human tumors. Retroperitoneal NETs are commonly metastatic originating from the pancreas and the gastrointestinal tract [1 , 2] . There are 2 main groups of NETs, divided on the basis of their cytoskeleton filaments.…”

Section: Introductionmentioning

confidence: 99%

Primary retroperitoneal neuroendocrine tumor with nonspecific presentation: A case report

Taei

Mail

Thinayyan

2020

Radiology Case Reports

View full text Add to dashboard Cite

show abstract

“…Primary NENs of the retroperitoneum are extremely rare, being more commonly the site of metastases from NETs with known primary. Only a few cases are reported in the literature [3].…”

Section: Case Reportmentioning

confidence: 99%

“…Of note, clinical trials and the most relevant retrospective studies generally do not include patients with NENs of atypical origin, thus a standardised therapeutic strategy has not been established in this particular subgroup. As a consequence, in clinical practice, well-and moderately-differentiated NENs (defined as neuroendocrine tumours with grading 1/2 or NENs G1/2) with atypical primary sites of origin, such as primary breast [2] and primary retroperitoneal NETs [3], are treated like more common primary ones -gastroenteropancreatic and thoracic NENs. However, increasing literature data suggest that the combina-tion chemotherapy of capecitabine and temozolomide (CAPTEM) could be a potentially useful treatment option for patients with grade 1/2 NENs of multiple origins [4][5][6][7][8][9][10].…”

Section: Introductionmentioning

confidence: 99%

Capecitabine plus temozolomide in well- or moderately-differentiated primary atypical neuroendocrine tumours — single-centre experience of two cases

Salvia

Brizzi

Muratori

et al. 2019

Endokrynologia Polska

View full text Add to dashboard Cite

Introduction: Neuroendocrine neoplasms (NENs) are a rare and heterogeneous group of tumours, with a variety of primary origins and variable aggressiveness. NENs with an atypical primary origin, such as breast and retroperitoneal NENs, are extremely rare. As a consequence, an established diagnostic and therapeutic strategy in this particular subgroup is lacking. The combination of capecitabine and temozolomide, called CAPTEM regimen, has produced promising response rates in patients with grade 1 or 2 neuroendocrine tumours of multiple origins. Case presentation: The first is a case of a 68-year-old woman with a metastatic primary breast neuroendocrine tumour, treated with cisplatin plus etoposide as first line, followed by CAV scheme (cyclophosphamide, doxorubicin, and vincristine), and subsequently treated, in third line with the CAPTEM regimen, obtaining radiological response and good tolerance. The second is the case of a 66-year-old woman affected by a metastatic primitive retroperitoneal NET G2. The patient progressed after a somatostatin analogue-based first line, whereas the CAPTEM regimen led to a partial and durable response with a favourable safety profile. Conclusions: CAPTEM chemotherapy has been shown to be an active and safe therapeutic option in advanced, metastatic G1/2 atypical primary NENs.

show abstract

“…NETs found in the retroperitoneum are mainly metastatic. Retroperitoneal paraganglioma usually arise from the adrenal medulla (80-90%), with the remainder (10-20%) arising from the paraaortic region [ 3 ].…”

Section: Introductionmentioning

confidence: 99%

Pseudotumoral form of schistosomiasis mimicking neuroendocrine tumor: a case report and brief review of the differential diagnosis of retroperitoneal masses

Marín-Martínez¹,

Kyriakos²,

Sánchez-Gutiérrez³

2020

Pan Afr Med J

View full text Add to dashboard Cite

Primary Epithelial Neuroendocrine Tumors of the Retroperitoneum

Cited by 12 publications

References 13 publications

Primary retroperitoneal neuroendocrine tumor with nonspecific presentation: A case report

Primary retroperitoneal neuroendocrine tumor with nonspecific presentation: A case report

Capecitabine plus temozolomide in well- or moderately-differentiated primary atypical neuroendocrine tumours — single-centre experience of two cases

Pseudotumoral form of schistosomiasis mimicking neuroendocrine tumor: a case report and brief review of the differential diagnosis of retroperitoneal masses

Contact Info

Product

Resources

About